---
title: "RHHBY.US (RHHBY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RHHBY.US/news.md"
symbol: "RHHBY.US"
name: "RHHBY.US"
parent: "https://longbridge.com/en/quote/RHHBY.US.md"
datetime: "2026-05-19T23:25:31.511Z"
locales:
  - [en](https://longbridge.com/en/quote/RHHBY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RHHBY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RHHBY.US/news.md)
---

# RHHBY.US (RHHBY.US) — Related News

### [Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer | RHHBY Stock News](https://longbridge.com/en/news/286856548.md)
*2026-05-18T21:00:00.000Z*
> Roche will present new data on giredestrant at the ASCO 2026 Annual Meeting, highlighting its potential as a standard tr

### [FDA approves Enhertu for two HER2-positive early breast cancer indications](https://longbridge.com/en/news/286740066.md)
*2026-05-18T07:49:17.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [10:30 ETCancer Biomarkers Market worth $54.48 billion by 2032 | MarketsandMarkets™](https://longbridge.com/en/news/286788905.md)
*2026-05-18T14:40:38.000Z*
> The Cancer Biomarkers Market is projected to grow from USD 28.25 billion in 2026 to USD 54.48 billion by 2032, at a CAGR

### [](https://longbridge.com/en/news/286717974.md)
*2026-05-18T05:30:27.000Z*
> AstraZeneca has reached a cooperation agreement with Roche Diagnostics in the Asia-Pacific region to jointly accelerate 

### [Nat Communi: Anti-cancer "multi-functional" new drug debuts! A team led by Shen Lin from Peking University showed through early clinical trials that it remains effective for patients with FGFR inhibitor-resistant cholangiocarcinoma](https://longbridge.com/en/news/286667226.md)
*2026-05-17T09:00:39.000Z*
> Tengtinib is a multi-kinase inhibitor that has shown efficacy in cholangiocarcinoma patients resistant to FGFR inhibitor

### [FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | RHHBY Stock News](https://longbridge.com/en/news/286594661.md)
*2026-05-15T08:45:31.000Z*
> FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | RHHBY Stock